AB
vs
D
DAX Index
AB
Over the past 12 months, AB has underperformed DAX Index, delivering a return of -9% compared to the DAX Index's +25% growth.
Stocks Performance
AB vs DAX Index
Performance Gap
AB vs DAX Index
Performance By Year
AB vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AB Science SA
Glance View
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.